Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant

Table 4 Clinical baseline characteristics and their predictive value for sustained viral response

	SVR		Non SVR		P ≤
Patients, n/%	11	60%	8	42%
Age, yr	53	41-70	58	53-64	0.1151
Body mass index (kg/m2)	26	22-30	26	21-33.1	0.5051
Ischak fibrosis score (grade)
I-II	7	64%	6	75%
III-IV	4	36%	2	25%
Fibroscan baseline (kPa)	14.6	4.5-23.4	11.3	5.9-26	0.7731
Time from LT to triple therapy (mo)	22	7-156	23	8-295	0.8691
Bilirubin total (mg/dL)	0.6	0.3-1.1	1	0.4-3.2	0.0301
GPT (ALT) (U/L)	46	21-159	40	24-85	0.5631
GOT (AST) (U/L)	52	18-84	53.5	22-88	0.6201
Platelet count (/μL)	143	68-246	103.5	63-236	0.3021
Viral load (log10 IU/mL)	1.9	0.39-14.9	4.2	0.13-13.70	0.4091
HCV GT					0.0492
1a, n/%	2	18%	4	50%
1b, n/%	9	81%	4	50%
Recipient IL-28b polymorphism, n/%					0.5522
CC	4	36%	1	12.50%
CT	3	27%	6	75%
TT	4	36%	1	12.50%
History of any prior PEG-INF/RBV treatment, n/%	7	63%	4	50%	0.5522
History of post-LT PEG-INF/RBV treatment, n/%	2	18%	3	37.50%	0.3452

¹Pearson's χ² test;

²Mann-Whitney-U-test, P≤ 0.05 set as statistic significant. HCV: Hepatitis C virus; PEG-INF: Pegylated-interferon; RBV: Ribavirine; SVR: Sustained viral response; LT: Liver transplantation; GT: Genotype; GPT: Glutamat pyruvat transaminase; GOT: Glutamat oxalacetat transaminase; ALT: Alanine aminotransferases; AST: Aspartate aminotransferase.